000099225 001__ 99225
000099225 005__ 20230914083313.0
000099225 0247_ $$2doi$$a10.3390/diagnostics10121036
000099225 0248_ $$2sideral$$a122738
000099225 037__ $$aART-2020-122738
000099225 041__ $$aeng
000099225 100__ $$aPin-Vieito, N.
000099225 245__ $$aPredictive Value of Carcinoembryonic Antigen in Symptomatic Patients without Colorectal Cancer: A Post-Hoc Analysis within the COLONPREDICT Cohort
000099225 260__ $$c2020
000099225 5060_ $$aAccess copy available to the general public$$fUnrestricted
000099225 5203_ $$aWe aimed to assess the risk of cancer in patients with abdominal symptoms after a complete colonoscopy without colorectal cancer (CRC), according to the carcinoembryonic antigen (CEA) concentration, as well as its diagnostic accuracy. For this purpose, we performed a post-hoc analysis within a cohort of 1431 patients from the COLONPREDICT study, prospectively designed to assess the fecal immunochemical test accuracy in detecting CRC. Over 36.5 +/- 8.4 months, cancer was detected in 115 (8%) patients. Patients with CEA values higher than 3 ng/mL revealed an increased risk of cancer (HR 2.0, 95% CI 1.3-3.1), CRC (HR 4.4, 95% CI 1.1-17.7) and non-gastrointestinal cancer (HR 1.7, 95% CI 1.0-2.8). A new malignancy was detected in 51 (3.6%) patients during the first year and three variables were independently associated: anemia (OR 2.8, 95% CI 1.3-5.8), rectal bleeding (OR 0.3, 95% CI 0.1-0.7) and CEA level >3 ng/mL (OR 3.4, 95% CI 1.7-7.1). However, CEA was increased only in 31.8% (95% CI, 16.4-52.7%) and 50% (95% CI, 25.4-74.6%) of patients with and without anemia, respectively, who would be diagnosed with cancer during the first year of follow-up. On the basis of this information, CEA should not be used to assist in the triage of patients presenting with lower bowel symptoms who have recently been ruled out a CRC.
000099225 536__ $$9info:eu-repo/grantAgreement/EUR/ISCII-ERDF/A way to make Europe$$9info:eu-repo/grantAgreement/ES/ISCIII-ERDF-FSE/PI17-00837$$9info:eu-repo/grantAgreement/ES/ISCIII-ESF/Investing in your future
000099225 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000099225 590__ $$a3.706$$b2020
000099225 591__ $$aMEDICINE, GENERAL & INTERNAL$$b45 / 167 = 0.269$$c2020$$dQ2$$eT1
000099225 592__ $$a0.622$$b2020
000099225 593__ $$aClinical Biochemistry$$c2020$$dQ3
000099225 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000099225 700__ $$aIglesias, M.J.
000099225 700__ $$aRemedios, D.
000099225 700__ $$aAlvarez-Sanchez, V.
000099225 700__ $$aFernandez-Banares, F.
000099225 700__ $$aBoadas, J.
000099225 700__ $$aMartinez-Bauer, E.
000099225 700__ $$aCampo, R.
000099225 700__ $$aBujanda, L.
000099225 700__ $$0(orcid)0000-0003-2280-9372$$aFerrandez, A.$$uUniversidad de Zaragoza
000099225 700__ $$aPinol, V.
000099225 700__ $$aRodriguez-Alcalde, D.
000099225 700__ $$aMenendez-Rodriguez, M.
000099225 700__ $$aGarcia-Morales, N.
000099225 700__ $$aPerez-Mosquera, C.
000099225 700__ $$aCubiella, J.
000099225 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000099225 773__ $$g10, 12 (2020), 1036 [13 pp]$$tDiagnostics$$x2075-4418
000099225 8564_ $$s422293$$uhttps://zaguan.unizar.es/record/99225/files/texto_completo.pdf$$yVersión publicada
000099225 8564_ $$s2547554$$uhttps://zaguan.unizar.es/record/99225/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000099225 909CO $$ooai:zaguan.unizar.es:99225$$particulos$$pdriver
000099225 951__ $$a2023-09-13-10:59:36
000099225 980__ $$aARTICLE